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Objective: Bone morphogenic protein (BMP)-2 and BMP-7 are clinically approved and their recombinant
proteins are used for bone tissue regenerative purposes and widely evaluated for cartilage regeneration.
Previous comparison of the in vitro chondrogenic characteristics of BMP-2 vs BMP-7 did not address
hypertrophic differentiation and characterizing their chondrogenic properties with a focus in on chon-
drocyte hypertrophy was topic of investigation in this study.
Design: Equimolar concentrations of BMP-2 or BMP-7 were added to chondrogenic differentiating ATDC5,
human bone marrow stem cells or rabbit periosteal explants. Expression of Col2a1, Sox9, Acan, Col10a1,
Runx2, ALP, Mmp13, Mef2c and Bapx1/Nkx3.2 was determined by reverse transcription-quantitative PCR
(RT-qPCR) and immunoblotting. Glycosaminoglycan content, cell proliferation capacity and ALP activity
were analysed by colourimetric analyses. Expression of Bapx1/Nkx3.2 and Sox9 was targeted by trans-
fection of target speciﬁc siRNA duplexes.
Results: BMP-2 dose-dependently increased chondrocyte hypertrophy during chondrogenic differentia-
tion of progenitor cells, whereas BMP-7 acted hypertrophy-suppressive and chondro-promotive. Both
BMPs did not inﬂuence cell proliferation, but they did increase total glycosaminoglycan content. In
a candidate approach Bapx1/Nkx3.2 was found to be involved in the BMP-7 mediated suppression of
chondrocyte hypertrophy in ATDC5 cells.
Conclusions: BMP-2 and BMP-7 display opposing actions on the chondrogenic outcome of differentiating
progenitor cells: BMP-2 acts a speciﬁc inducer of chondrocyte hypertrophy, while BMP-7 appears to
increase or maintain chondrogenic potential and prevent chondrocyte hypertrophy. Our results pave the
way for an application-dependent differential use of BMP-2 or BMP-7.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Methodologies controlling chondrogenic differentiation of
mesenchymal progenitor cells towards chondrocytes are of interest
to improve the outcome of skeletal regenerative medicine ap-
proaches. During chondrogenic differentiation mesenchymal pro-
genitor cells condensate and differentiate into proliferating and
extracellular matrix synthesizing chondrocytes which, in the case
of endochondral ossiﬁcation and different cartilage pathologies,
ultimately terminally differentiate into hypertrophic mineralized
chondrocytes1,2. For progenitor cell-based cartilage regeneration it
is therefore crucial to ﬁnd optimal strategies to stimulateT.J.M. Welting, P.O. Box 5800,
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s Research Society International. Pprogenitor cells to differentiate into chondrocytes and preventing
them from hypertrophy and mineralization3,4. On the contrary, for
bone tissue engineering, promoting terminal differentiation
through endochondral ossiﬁcation may be advantageous5.
Bone morphogenic proteins (BMPs) are important soluble me-
diators for tuning a variety of cellular processes including cell
proliferation and differentiation. Especially BMP-2 and BMP-7 (also
known as osteogenic protein-1 (OP-1)) are clinically approved and
are widely evaluated for cartilage and bone tissue regenerative
purposes6e8. BMPs are involved in all phases of chondrogenic dif-
ferentiation and are able to directly regulate expression of several
chondrocyte speciﬁc genes9,10. BMP-2 is described to promote cell
proliferation and matrix synthesis in human articular chon-
drocytes, growth plate chondrocytes and developing mouse
limbs11e13. Moreover, BMP-2 has been demonstrated to regulate
the expression and activity of Sox9 (SRY (sex determining region Y)
box9)14,15. BMP-7 is described to promote in vitro chondrogenic
extracellular matrix synthesis in normal and osteoarthritic human
articular chondrocytes11,16e18 and can counteract retinoic acid-ublished by Elsevier Ltd. All rights reserved.
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BMP-7 also promotes chondrogenic differentiation of human and
goat perichondrium cells, developing mouse limbs and human
chondrocytes20.
Although these BMPs are clinically used and their potential is
widely explored in cartilage/bone regenerative approaches, the
hypertrophic properties of BMP-2 vs BMP-7 are not well docu-
mented. We aimed to compare the action of BMP-2 and BMP-7 on
chondrogenic differentiation of progenitor cells, focussing on hy-
pertrophic differentiation.
Methods
ATDC5 cell culture
ATDC5 were cultures in proliferation medium consisting of
Dulbecco's minimal essential medium (DMEM)/F12 (Invitrogen),
5% fetal calf serum (FCS) (PAA), 1% antibiotic/antimycotic (Invi-
trogen) and 1% NEAA (non-essential amino acids; Invitrogen).
ATDC5 were differentiated in differentiation medium comprising
proliferation medium supplemented with 10 mg/ml insulin (Sigma),
10 mg/ml transferrin (Roche) and 30 nM sodium selenite (Sigma).
Cells were plated at 6400 cells/cm2 and chondrogenic differentia-
tion was initiated by adding differentiation medium. BMP-2
(Sigma) or BMP-7 (R&D Systems) were used in equimolar concen-
trations. For comparison, 1 nM BMP-2 corresponds to 31 ng/ml
and 1 nM BMP-7 corresponds to 26 ng/ml. A Bapx1/Nkx3.2
siRNA duplex (sense: 50-CAGAGACGCAAGUGAAGAUTT-30, anti-
sense: 50-AUCUUCACUUGCGUCUCUGTT-30), Sox9 siRNA duplex
(sense: 50-GACUCACAUCUCUCCUAAUTT-30, anti-sense: 50-AUUAG-
GAGAGAUGUGAGUCTT-30) and scrambled siRNA duplex (indicated
by “Mock”) were used (Eurogentec). ATDC5 cells were seeded at
25,000 cells/cm2 and transfection (50 nM) was performed using
ICAfectin 442 (Eurogentec) according to manufacturers’ protocol.
This resulted in an average transfection efﬁciency of 75% in these
experiments (determined by ﬂuorescence microscopy of 50 ﬂuo-
rescein isothiocyanate (FITC) labelled variants of the respective
siRNAs). Transfected cells were cultured for 1 day before chon-
drogenic differentiation was initiated and retransfection of siRNAs
was carried out at 2 and 5 days.
Human bone marrow stem cells (hBMSC) isolation and cell culture
hBMSCs were obtained from iliac crest bone marrow aspirate
from young, genetically healthy individuals (MEC MUMC approval
08-4-056). hBMSCs were isolated using Ficoll-Paque PLUS (Amer-
sham Pharmacia). Culture medium consisted of DMEM high glu-
cose (Invitrogen), 10% FCS, 1% antibiotic/antimycotic and 1% NEAA.
Chondrogenic differentiation was performed in monolayer by
plating passage ﬁve cells at 30,000 cells/cm2. Differentiation me-
dium consisted of proliferation medium supplemented with 1%
insuline transferrin selenite (ITS) (Invitrogen), 50 mg/ml L-ascorbic
acid-2-phosphate (Sigma) and 1 ng/ml TGFb3 (R&D)21,22. BMP-2 or
BMP-7 were used in equimolar concentrations as described above.
Periosteum agarose culture (PAC)
As previously described23, periosteum was harvested from the
proximal tibia of skeletally mature New Zealand white (NZW)-
rabbits. Post-mortem animals were obtained from an unrelated
study, no ethical approval was necessary. Periosteumwas prepared
as a 3 3mm piece and embedded between a layer of highmelting
agarose (1%) and low melting agarose (1%) according to O’Driscoll
et al.24, and proliferation medium (DMEM/F12, 10% FCS, 1% P/S, 1%
NEAA) was added. After overnight incubation, medium waschanged to differentiation medium (proliferation medium supple-
mented with 1% ITS, 50 mg/ml L-ascorbic acid-2-phosphate, 10 ng/
ml TGFb3) and PACs were differentiated for 20 days with medium
changes every 3 days. BMP-2 or BMP-7 were used in 30 ng/ml
equimolar concentrations as described above.
RT-qPCR
For RNA isolation, cells were washed three times with 0.9% NaCl
and disrupted with 500 ml Trizol (Invitrogen). To isolate total RNA
from PAC cultures, tissue was cut in pieces and soaked overnight in
500 ml Trizol at 4C. RNA isolation, RNA quantiﬁcation by ultraviolet
(UV)-spectrometry (Nanodrop, Thermo Scientiﬁc), and cDNA syn-
thesis were performed as described before21. Real-time quantitative
PCR (RT-qPCR) was performed using Mesagreen qPCR mastermix
plus for SYBR Green (Eurogentec). An Applied Biosystems ABI
PRISM 7700 Sequence Detection System was used for ampliﬁca-
tion: initial denaturation 95C for 10 min, followed by 40 cycles of
DNA ampliﬁcation (denaturing 15 s at 95C and annealing 1 min at
60C). Data were analysed using the standard curve method, mRNA
expression was normalized to a reference gene (b-actin (ATDC5,
rPACs) and 28S rRNA (hBMSCs)) and gene expression was calcu-
lated as fold increase as compared to day 0. Validated primer se-
quences are depicted in Table I.
Immunoblotting
Cells were washed with 0.9% NaCl and lysed in radio-
immunoprecipitation assay (RIPA) buffer. Extracts were sonicated
on ice using the Soniprep 150 (MSE) at amplitude 10 for 14 cycles
(1 s sonication and 1 s pause). Insoluble material was removed by
centrifugation (13,000  g, 4C). Protein concentration was deter-
mined using the bicinchoninic acid (BCA) protein assay (Sigma).
Polypeptides were separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) (samples were
equally loaded) and transferred to nitrocellulose membranes by
electroblotting. Primary antibodies for immunodetection were
polyclonal goat anti-Col2a1 (Southern Biotech), polyclonal rabbit
anti-Col10a1 (Calbiochem), polyclonal goat anti-Sox9 (Abcam),
mouse monoclonal anti-Runx2 (MBL), polyclonal rabbit anti-Bapx1
(Abcam) and mouse monoclonal anti-a-Tubulin (Sigma). Bound
primary antibodies were detected with secondary immunoglobu-
lins conjugated with horseradish peroxidase (DakoCytomation)
and visualized by enhanced chemiluminescence (ECL). ECL signals
were quantiﬁed using ImageJ 1.46f software. Relative differences,
corrected for background and housekeeper, were determined as
compared to control conditions.
Alcian blue staining
Glycosaminoglycan content was detected by Alcian blue stain-
ing. Cells were washed with 0.9% NaCl and ﬁxed with 4% paraf-
ormaldehyde (Merck) in phosphate buffered saline for 10 min at
room temperature, washed with water and air dried. After over-
night incubation with 1% Alcian blue (Acros VWR) in 0.1 M HCl at
room temperature, cells werewashed six times and Alcian bluewas
extracted by incubation with Guanidine-HCl (6 M) (Sigma) for 2 h
under continuous agitation. Extracted Alcian blue was determined
spectrophotometrically at 645 nm using a plate reader (Multiskan
FC, Thermo Scientiﬁc).
Alkaline phosphatase activity
Cells were lysed in freshly prepared collection buffer (1.5 M
TriseHCl pH 9.0; 2% (v/v) Triton X-100) and homogenized by
Table I
DNA oligo sequences for RT-qPCR. Forward and reverse oligo sequences (50e30) used for RT-qPCR are listed for mouse, human and rabbit
Forward Reverse
Oligo sets mouse
Col2a1 50-TGGGTGTTCTATTTATTTATTGTCTTCCT-30 50-GCGTTGGACTCACACCAGTTAGT-30
Co110a1 50-CATGCCTGATGGCTTCATAAA-30 50-AAGCAGACACGGGCATACCT-30
Sox9 50-AGTACCCGCACCTGCACAAC-30 50-TACTTGTAGTCCGGGTGGTCTTTC-30
Acan 50-CATGAGAGAGGCGAATGGAA-30 ’5-TGATCTCGTAGCGATCTTTCTTCT-30
Runx2 50-GACGAGGCAAGAGTTTCACC-30 50-GGACCGTCCACTGTCACTTT-30
Mmp13 50-CGATGAAGACCCCAACCCTAA-30 50-ACTGGTAATGGCATCAAGGGATA-30
ALP 50-CCGATGGCACACCTGCTT-30 50-GGAGGCATACGCCATCACAT-30
Mef2c 50-GGGCCTCAATGGCTGTGA-30 50-CTCAGACTCAGGGCTGTGACCTA-30
Bapx1/Nkx3.2 50-GCGTGACGACCAAAGACAGTATTT-30 50-GGGAGACAGTAGTAAGGGTAGTAGTAGGA-30
b-Actin 50-GACAGGATGCAGAAGGAGATTACTG-30 50-CCACCGATCCACACAGAGTACTT-30
Oligo sets human
COL2A1 50-TGGGTGTTCTATTTATTTATTGTCTTCCT-30 50-GCGTTGGACTCACACCAGTTAGT-30
COL10A1 50-ATGATGAATACACCAAAGGCTACCT-30 50-ACGCACACCTGGTCATTTTCTG-30
RUNX2 50-TGATGACACTGCCACCTCTGA-30 50-GCACCTGCCTGGCTCTTCT-30
28S rRNA 50-GCCATGGTAATCCTGCTCAGTAC-30 50-GCTCCTCAGCCAAGCACATAC-30
Oligo sets rabbit
Col2a1 50-TGGGTGTTCTATTTATTTATTGTCTTCCT-30 05-GCGTTGGACTCACACCAGTTAGT-30
Co110a1 50-AACCTGGACAACAGGGACTTACA-30 50-CCATATCCTGTTTCCCCTTTCTG-30
Runx2 50-TGATGACACTGCCACCTCTGA-30 50-GCACCTGCCTGGCTCTTCT-30
b-Actin 50-GACAGGATGCAGAAGGAGATTACTG-30 50-CCACCGATCCACACAGAGTACTT-30
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centrifugation (5 min; 13,000 g; 4C). Total protein concentration
was determined (see above). ALP activity was determined by in
time measuring ALP-depend enzymatic conversion of p-nitro-
phenyl phosphate to nitrophenyl phosphate in buffer containing
1.5 M TriseHCl; pH 9.0, 1 mM ZnCl2, 1 mM MgCl2 and 7.5 mM p-
nitrophenyl phosphate. Substrate conversion was spectrophoto-
metrically quantiﬁed at 405 nm. A calibration curve consisted of an
increasing concentration of nitrophenyl phosphate to determine
the absolute amount of ALP-generated nitrophenyl phosphate in
time. Values were normalized to total protein and expressed as
mmol nitrophenyl phosphate/minute/gram (¼1U).
Cell proliferation
Cells were washed with 0.9% NaCl and ﬁxated with 4% paraf-
ormaldehyde (Merck) in phosphate buffered saline for 10 min at
room temperature, washed with water and air dried. Cells were
incubated with 0.1% X-violet (Sigma) for 30 min at room temper-
ature and washed six times with water. X-violet was extracted
from the cells by incubation with 10% acetic acid for 15 min under
continuous agitation. Extracted X-violet was determined spec-
trophotometrically at 590 nm using a plate reader (Multiskan FC,
Thermo Scientiﬁc).
Histochemistry
PACs were decalciﬁed in formalin/EDTA, dehydrated following
standard procedures and embedded in parafﬁn. Before histo-
chemistry, tissue sections (5 mm) were deparaﬁnized and rehy-
drated using standard protocols. Proteoglycans were stained with
Safranin-O (0.1%) and counterstained with Fast Green (0.1%).
Stained sections were dehydrated and mounted in Histomount
(Thermo Shandon) for microscopic analysis.
Statistics
In the Figures based on ATDC5, bars represent average value of
three individual experiments (performed in triplicate; 3 samples)
and error bars represent mean 95% conﬁdence interval (CI). In the
experiments using hBMSCs or rPACs, all experiments were per-
formed in triplicate with hBMSCs from three independent donors(n ¼ 3) or rabbit periosteal explants from ﬁve independent donors
(n ¼ 5). Statistical signiﬁcance (P < 0.05) was determined by un-
paired two-tailed student t-tests (paired two-tailed Student t test
for data derived from hBMSC experiments [Fig. 3(A)] using
GraphPad PRISM 5.0 (La Jolla, CA, USA)). To test for normal distri-
bution of the input data, D’AgostinoePearson omnibus normality
tests were performed. All quantitative data sets presented here
passed the normality tests. Using an F-test homogeneous variance
of the input data was conﬁrmed.
Results
Differential effects of BMP-2 and BMP-7 on chondrogenic
differentiation of progenitor cells
To determine whether BMP-2 and BMP-7 differently inﬂuence
the outcome of chondrogenic differentiation of progenitor cells we
performed doseeresponse experiments to establish the minimal
BMP concentrations that lead to detectable changes in the chon-
drogenic outcome. As presented in Fig. 1(A), 0.01 and 0.1 nM of
BMP-2 (grey bars) did not inﬂuence the mRNA expression of Col-
lagen type II (Col2a1), although a slight increase was detected at
1.0 nM. On the other hand, BMP-7 (black bars) dose-dependently
increased Col2a1 expression. Collagen type X (Col10a1) mRNA
expression [Fig. 1(B)] revealed a dose-dependent increase upon
BMP-2 exposure, whereas BMP-7 led to a Col10a1 suppressing ac-
tion. From these experiments we decided to use 1 nM of both BMPs
throughout the rest of our experiments, as this dose was the min-
imal concentration needed to detect BMP-induced changes in
chondrogenic gene expression.
To obtain further insight into the action of the different BMPs
during chondrogenic differentiation we determined the expression
of Col2a1 and Col10a1 at different time points (0, 7, 10 and 14 days)
in ATDC5 differentiation. A gradual increase was found in Col2a1
and Col10a1 mRNA levels throughout the 14-day timeframe
[Fig. 2(A); white bars]. Addition of 1 nM BMP-2 (grey bars) resulted
in a slight increase in Col2a1 mRNA and protein synthesis during
chondrogenic differentiation [Fig. 2(A/C)]. Col10a1 mRNA and
protein levels were higher increased in the BMP-2 condition, as
compared to the control condition [Fig. 2(B/C)]. Addition of an
equimolar concentration of BMP-7 (black bars) resulted in
increased Col2a1 mRNA and protein levels [Fig. 2(A/C)], whereas
Fig. 2. Differential effects of BMP-2 and BMP-7 on the chondrogenic outcome of ATDC5 cells. Equimolar concentrations (1 nM) of BMP-2 or BMP-7 were added from the start of
chondrogenic differentiation of ATDC5. A: Col2a1 mRNA expression at day 7, 10 and 14 in differentiation, relatively to t ¼ 0. White bars represent control condition, grey bars the BMP-2
condition and black bars the BMP-7 condition. B: Same as in (A) but for Col10a1. C: Protein expression of Col2a1, Sox9, Col10a1 and Runx2 at day 14 in differentiation. a-Tubulin is used as
loading control. D: Induction of Sox9 and Acan mRNA expressionwas determined at day 14 in differentiation. E: Induction of Runx2, ALP and Mmp13 mRNA expressionwas determined
at day 14 in differentiation. F: ALP enzymatic activity ((U) mmol/g/min) of t ¼ 14 samples was determined and normalized to total protein content. G: Glycosaminoglycan content was
determined by Alcian Blue staining and fold increase of t ¼ 14 samples was calculated relatively from t ¼ 0 samples. H: Differences in cell proliferation speed between control and BMP
conditions in ATDC5 differentiationwas determined by X-Violet staining. Fold increase (DNA) from samples from t ¼ 14 was calculated relatively to day 0. In graphs, error bars represent
mean  95% CI. Statistics are calculated with respect to the control condition (P-values are depicted on top of bars) and between BMP-2 and BMP-7 conditions. Statistical signiﬁcant
P-values (P < 0.05) are shown in bold. Molecular weight markers (kDa) are depicted on the left of immunoblots and relative quantiﬁcations are depicted on top of blots.
Fig. 1. Effects of increasing BMP-2 or BMP-7 concentrations on chondrogenic differentiation of ATDC5 cells. Equimolar concentrations (0, 0.01; 0.1 or 1 nM) of BMP-2 or BMP-7 were
added from the start of chondrogenic differentiation of ATDC5. A: Col2a1 mRNA expression at day 14 in differentiation, relatively to t ¼ 0. White bars represent control (0 nM)
condition, grey bars the different BMP-2 concentrations and black bars the different BMP-7 concentrations. B: Same as in (A) but for Col10a1. In graphs, error bars represent
mean  95% CI. Statistics are calculated with respect to the control condition and P-values are depicted on top of bars. Statistical signiﬁcant P-values (P < 0.05) are shown in bold.
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10 on, as compared to control [Fig. 2(B/C)] and as compared to the
BMP-2 condition [Fig. 2(B/C); black vs grey bars]. Expression of
Sox9 reacted mildly to BMP-2 exposure, whereas challenging the
cells with BMP-7 led to higher upregulated Sox9 levels [Fig. 2(C/D)].
Aggrecan (Acan) gene expression also reacted very similar (to Sox9
and Col2a1) upon exposure to both individual BMPs. Analogous to
our above ﬁndings on Col10a1 expression, the expression of other
chondrocyte hypertrophy genes as Runx2 (Runt related transcrip-
tion factor 2), ALP (Alkaline phosphatase) and Mmp13 (Matrix
metalloproteinase 13) was found to be increased in the BMP-2
condition (grey bars) as compared to control differentiation con-
ditions (white bars) and suppressed in the BMP-7 condition (black
bars) [Fig 2(C/E)]. Expression of these hypertrophy-associated
genes was also found to be signiﬁcantly different between the
BMP-2 and the BMP-7 condition [Fig. 2(E)]. A hypertrophy-inducing
action of BMP-2 and hypertrophy-suppressive action by BMP-7 was
further conﬁrmed by measuring ALP enzymatic activity in these
cultures [Fig. 2(F)]. As an overall indicator for glycosaminoglycan
content, alcian blue stainings revealed that both BMPs caused
increased glycosaminoglycan content in differentiating ATDC5 cells
at day 14, as compared to control differentiation conditions
[Fig. 2(G)]. No signiﬁcant differences were detected between the
glycosaminoglycan contents of BMP-2 vs BMP-7 treated cells.
Interestingly, no signiﬁcant differences between control, BMP-2
and BMP-7 were found when cell proliferation capacity was
determined [Fig. 2(H)], indicating that both BMPs do not inﬂuence
the cell proliferation rate in the herein tested setting.
To verify our ATDC5 ﬁndings in primary human mesenchymal
progenitor cells, we supplemented the differentiation medium of
hBMSCs with equimolar concentrations (1 nM) of either two BMPs.
Chondrogenic differentiation of three individual hBMSC isolates led
to upregulation of COL2A1, COL10A1 and RUNX2 mRNAs at day 14
and 21 in differentiation [Fig. 3(A); white bars]. The addition of
1 nM BMP-2 increased the mRNA expression of COL10A1 andFig. 3. Differential effects of BMP-2 and BMP-7 on chondrogenic differentiation of hBMSCs an
added from the start of chondrogenic differentiation of hBMSCs (n ¼ 3 individual donors) or
day 14 and 21 in hBMSC chondrogenic differentiation, relatively to t ¼ 0. White bars repres
condition. B: Protein expression of COL2A1 and COL10A1 at day 21 in chondrogenic differen
(kDa) are depicted on the left. C: rPAC’s were harvested after 20 days of chondrogenic differe
Safranin-O/Fast Green. Magniﬁcation is 200. D: Col2a1, Col10a1 and Runx2 mRNA expres
represent control condition, grey bars the BMP-2 treated condition and black bars the BMP
individual BMSC donors (n ¼ 3) or triplicate samples of ﬁve individual rPAC donors (n ¼ 5) a
the donor dispersion. Statistics are calculated with respect to the control condition (P-valu
signiﬁcant P-values (P < 0.05) are shown in bold.RUNX2, while leaving COL2A1 mRNA levels almost unchanged
[Fig. 3(A); grey bars]. However, addition of 1 nM BMP-7 to the
differentiation medium resulted in signiﬁcantly increased COL2A1
mRNA expression, while COL10A1 and RUNX2 mRNA expression
was suppressed at day 21 [Fig. 3(A); black bars]. Immunoblot
analysis of protein lysates from day 21 samples overall conﬁrmed
the above ﬁndings [Fig. 3(B)]. To establish the opposing actions of
BMP-2 and BMP-7 in cartilage tissue formation we used an ex vivo
periosteal organ culture system able to differentiate into cartilagi-
nous tissue23,24. The mesenchymal progenitor cell-containing per-
iosteal tissue was differentiated in between agarose layers (PAC)
under inﬂuence of TGFb3 and generated cartilaginous tissue after
20 days in differentiation, as visualized by Safranin-O staining of
tissue sections [Fig. 3(C)]. The cartilaginous tissue expressed
Col2a1, Col10a1 and Runx2 mRNAs [Fig. 3(D)]. BMP-2 supplemen-
tation showed an increased hypertrophic phenotype [Fig. 3(C)] as
well as increased Col2a1, Col10a1 and Runx2 gene expression (grey
bars). On the contrary, BMP-7 speciﬁcally increased Col2a1 mRNA
expression, but showed a decreased Col10a1 and Runx2 mRNA
expression as opposed to the control and BMP-2 conditions (black
bars).
Together these data show that exposure to equimolar concen-
trations of BMP-2 or BMP-7 evokes differential chondrogenic out-
comes during differentiation of ATDC5 cells, hBMSCs and rabbit
periosteal explants; BMP-2 stimulates chondrocyte hypertrophy,
whereas BMP-7 suppresses chondrocyte hypertrophy in the herein
tested equimolar concentrations.
Involvement of Bapx1/Nkx3.2 in mediating the hypertrophy-
suppressing action of BMP-7 in ATDC5 cells
As BMP-2 and BMP-7 display differential effects on the chon-
drogenic outcome of progenitor cells it is expected that both BMPs
differently direct pathways that balance the chondrogenic/hyper-
trophic fate of these cells. An important regulator in determiningd rabbit periosteal explants. Equimolar concentrations (1 nM) of BMP-2 or BMP-7 were
rPACs (n ¼ 5 individual donors). A: COL2A1, COL10A1 and RUNX2 mRNA expression at
ent control condition, grey bars the BMP-2 treated condition and black bars the BMP-7
tiation of hBMSCs. a-Tubulin is used as loading control and molecular weight markers
ntiation. The panel shows representative examples of rPAC tissue sections stained with
sion at day 20 in chondrogenic differentiation or rPACs, relatively to t ¼ 0. White bars
-7 condition. In graphs, bars represent the average value of triplicate samples of three
nd error bars represent mean  95% CI. Overlaying dot-plots are presented to visualize
es are depicted on top of bars) and between BMP-2 and BMP-7 conditions. Statistical
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factor has been linked to preventing chondrocyte hypertrophy
and maintaining a chondrogenic phenotype25,27,28. To determine
whether Bapx1/Nkx3.2 may play a role as a downstream effector in
the differential actions of BMP-2 and BMP-7 during chondrogenic
differentiation, we measured Bapx1/Nkx3.2 expression levels in
similar samples from Fig. 2. As previously reported27, upregulation
of Bapx1/Nkx3.2 expression was inversely correlated with pro-
gression in chondrogenic differentiation [Fig. 4(A); white bars].
Expression of Bapx1/Nkx3.2 hardly responded to the presence of
1 nM BMP-2 [Fig. 4(A); grey bars and immunoblot]. In contrast an
equimolar concentration of BMP-7 caused a signiﬁcantly increased
expression of Bapx1/Nkx3.2 [Fig. 4(A); black bars and immunoblot],
indeed suggesting an involvement in the hypertrophy-suppressing
action of BMP-7. To further investigate a potential functional
involvement of Bapx1/Nkx3.2 in the BMP-7 action, Bapx1/Nkx3.2
expression was targeted in ATDC5 cells by RNAi. Transfection of
a Bapx1/Nkx3.2 siRNA duplex during the course of chondrogenic
differentiation (in the absence of added BMP-7) showed knock-
down of Bapx1/Nkx3.2 mRNA as well as its protein expression atFig. 4. Bapx1/Nkx3.2 is involved in regulating the hypertrophic fate of ATDC5 cells. The in
mined. A: Bapx1/Nkx3.2 mRNA expression was determined in similar samples as Fig. 2(A/
entiation in the absence or presence of equimolar concentrations of BMP-2 or BMP-7 (1 nM
grey bars) mRNA expression was conﬁrmed at day 10 in differentiation (left and middle pan
Col2a1 and Acan mRNAs was determined in Mock and Bapx1/Nkx3.2 knockdown cells (B) a
Mef2c and ALP was determined. E: Protein expression of Col2a1, Sox9, Col10a1 and Runx2 in
bars represent mean  95% CI. Statistics are calculated with respect to the control conditi
between Bapx1/Nkx3.2 and Sox9 siRNA treated conditions. Statistical signiﬁcant P-values
molecular weight markers (kDa) are depicted on the left of immunoblots and relative quanten days in differentiation [Fig. 4(B); black striped bar and immu-
noblot]. Previously, transcription of Bapx1/Nkx3.2 was reported to
be driven by Sox925. In accordance with this we found that Sox9
expression only slightly, but not signiﬁcantly, responded to Bapx1/
Nkx3.2 knockdown [Fig. 4(B); black striped bar and immunoblot],
as did Sox9 transcriptional targets Col2a1 and Acan [Fig. 4(C/E)]. On
the other hand, knockdown of Sox9 [Fig. 4(B); grey striped bar]
downregulated the expression of Bapx1/Nkx3.2 to the same extend
as the dedicated Bapx1/Nkx3.2 knockdown, conﬁrming that Sox9
mainly acts upstream of Bapx1/Nkx3.2 expression. Messenger RNA
and protein expression of the Bapx1/Nkx3.2 repressional target
Runx2 was increased upon Bapx1/Nkx3.2 knockdown [Fig. 4(D/E)].
Along with Runx2 other important chondrocyte hypertrophy-
associated genes Col10a1, Mef2c (Myocyte-speciﬁc enhancer fac-
tor 2c) and ALP expression were also upregulated when expression
of Bapx1/Nkx3.2 was inhibited [Fig. 4(D/E)]. We subsequently
determined if the hypertrophy-suppressing effect of BMP-7 during
chondrogenic differentiation is related to the above Bapx1/Nkx3.2
action. We now transfected differentiating ATDC5 cells with the
Bapx1/Nkx3.2 siRNA duplex in the absence or presence of 1 nMvolvement of Bapx1/Nkx3.2 in hypertrophic differentiation of ATDC5 cells was deter-
B). Right panel shows protein expression of Bapx1/Nkx3.2 at day 14 in ATDC5 differ-
). B: RNAi mediated knockdown of Bapx1/Nkx3.2 (striped black bars) or Sox9 (striped
els). Protein expression in similar samples is shown in the right panel. C: Expression of
t day 10 in differentiation. D: In samples from (C) mRNA expression of Runx2, Col10a1,
Mock and Bapx1/Nkx3.2 knockdown cells at day 10 in differentiation. In graphs, error
on (P-values are depicted on top of bars), between BMP-2 and BMP-7 conditions and
(P < 0.05) are shown in bold. For immunoblots, a-Tubulin is used as loading control,
tiﬁcations are depicted on top of blots.
Fig. 5. Bapx1/Nkx3.2 is involved in the hypertrophy-suppressing action of BMP-7 in ATDC5 cells. The involvement of Bapx1/Nkx3.2 in the hypertrophy-suppressing action of BMP-7
during chondrogenic differentiation of ATDC5 cells was determined. A: Knockdown of Bapx1/Nkx3.2 by siRNA transfections was conﬁrmed at day 10 in differentiation of BMP-7
treated cells on mRNA (left panel, grey striped bars) and protein level (right panel). B: Expression of Sox9, Col2a1 and Acan mRNAs was determined in Mock (white and black bars,
without/with BMP-7 respectively) and Bapx1/Nkx3.2 knockdown cells (grey striped bars) at day 10 in differentiation in BMP-7 treated cells. C. In samples from (B.) mRNA expression
of Col10a1, Runx2, Mef2c and ALP was determined. D. Protein expression of Col2a1, Sox9, Col10a1 and Runx2 in Mock and Bapx1/Nkx3.2 knockdown cells at day 10 in differentiation
of BMP-7 treated cells. In graphs, error bars represent mean  95% CI. Statistics are calculated with respect to the control condition and BMP-7 control condition, as well as between
the BMP-7 control condition and the BMP-7/Bapx1 kd condition, Statistical signiﬁcant P-values (P < 0.05) are shown in bold. For immunoblots, a-Tubulin is used as loading control,
molecular weight markers (kDa) are depicted on the left of immunoblots and relative quantiﬁcations are depicted on top of blots.
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mRNA expression [Fig. 5(A); black bar] and the Bapx1/Nkx3.2 siRNA
duplex effectively downregulated the BMP-7-induced Bapx1/
Nkx3.2 expression [Fig. 5(A); grey striped bar vs black bar]. In
accordance with Fig. 4(B), Bapx1/Nkx3.2 knockdown in the pres-
ence of BMP-7 did not signiﬁcantly affect Sox9 mRNA expression,
and only a slight, but not signiﬁcant, decrease in Col2a1 and Acan
mRNA expression was observed [Fig. 5(B)]. In contrast, we did
observe clear effects on expression of chondrocyte hypertrophic
genes. Despite the presence of BMP-7, Bapx1/Nkx3.2 knockdown
completely abolished the hypertrophy-suppressing effect of BMP-7.
Expression levels of Col10a1, Runx2, Mef2c and ALP returned back
to control condition-levels or even higher [Fig. 5(C/D)], showing
that Bapx1/Nkx3.2 is involved in the hypertrophy-suppressing ac-
tion of BMP-7 during chondrogenic differentiation of ATDC5 cells.
In conclusion, we here show that BMP-2 and BMP-7 have dif-
ferential effects on the chondrogenic outcome of differentiating
chondroprogenitor cells: BMP-2 acts a speciﬁc inducer of chon-
drocyte hypertrophy, while BMP-7 appears to increase or maintain
chondrogenic potential and is able to suppress the level of chon-
drocyte hypertrophy via Bapx1/Nkx3.2.
Discussion
Although BMP-2 and BMP-7 are both potential targets in carti-
lage regenerative approaches, a comparison of the effects of BMP-2
vs BMP-7 on chondrogenic differentiation of progenitor cells
in vitro is not well documented and not taking chondrocyte hy-
pertrophy into account. We here report that BMP-2 and BMP-7
display opposing actions on the outcome of chondrogenic differ-
entiation of progenitor cells; BMP-2 stimulates a hypertrophic
chondrocyte phenotype, whereas BMP-7 appears to suppress
chondrocyte hypertrophy during chondrogenic differentiation,associated with an increased chondrogenic phenotype. A hyper-
trophy stimulating action was reported previously for BMP-223,
whereas the hypertrophy-suppressing action of BMP-7 is an
exciting new ﬁnding. Chubinskaya and colleagues reported that
BMP-2 but even more BMP-7 was able to increase proteoglycan
synthesis in adult human articular chondrocytes cultured in algi-
nate beads11. This indeed suggests that BMP-7 predominantly acts
in favour of a chondrogenic phenotype. Data reported by Shintani
et al., are supporting our ﬁndings. The authors reported on a more
pronounced beneﬁcial action of BMP-7 as opposed to BMP-2 on
chondrogenic outcome of bovine synovial explants, but hardly
addressed the effects on chondrocyte hypertrophy29. Similarly,
Kurth and colleagues compared different TGFb-superfamily mem-
bers and other factors for their chondrogenic potential on human
synovial mesenchymal stem cells, but also excluded hypertrophic
genes from their analyses30. In addition, Knippenberg et al. showed
that short-term treatment (15 min) of undifferentiated mesen-
chymal progenitor cells with BMP-2 resulted in differentiation to-
wards the osteogenic lineage, whereas short-term BMP-7
treatment increased chondrogenic marker expression31. The ma-
jority of the literature however reports on the individual effects of
BMP-2 or BMP-7 on chondrogenic outcome of progenitor cell dif-
ferentiation13,20,30,32e34.
Studies reporting on the use of BMPs in in vitro and ex vivo cell/
cartilage models used various concentrations of both BMPs ranging
from 10 ng/ml31 to as high as 500 ng/ml35. The BMP concentrations
that were tested in our dose response experiments (Fig. 1) are
relatively low as compared to the majority of the published studies.
As our main aimwas to investigate whether BMP-2 and BMP-7may
display differential actions, we hypothesized that an inverse lim-
iting dilution approach would be the most sensitive way to com-
pare both BMPs, while avoiding the risk of growth factor overload
and potential aspeciﬁc use of BMP receptors36,37. It remains
M.M.J. Caron et al. / Osteoarthritis and Cartilage 21 (2013) 604e613 611however to be determined how higher concentrations of both
BMPs would compare in their chondrogenic actions on the herein
tested chondrogenic models.
In analogy to the process of chondrogenic differentiation, dif-
ferent BMPs are expressed in different zones of the growth plate
and it is thus likely that these BMPs exert differentiation-phase
dedicated functions in regulating chondrogenic development.
BMP-2 is expressed by hypertrophic chondrocytes whereas BMP-7
is mainly expressed by proliferating chondrocytes38. Also the BMP
type I receptors, which activate R-Smad signalling, display differ-
ential expression patterns in the developing growth plate. BMP
receptor type IA (BMPR-IA or ALK (activin receptor-like kinase) 3) is
expressed by proliferating and hypertrophic chondrocytes, BMPR-
IB (also known as ALK6) is found throughout the growth plate
and ALK2 is detected in the resting zone and proliferating chon-
drocytes. These receptors do not bind all BMPs with similar afﬁnity
and can thus potentially induce different chondrogenic outcomes.
BMP-2 preferentially binds to BMPR-IA and BMPR-IB, whereas
BMP-7 binds with higher afﬁnity to ALK2 and BMPR-IB36,38,39,
which could suggest a more prominent function for BMP-2 in
chondrocyte hypertrophy and for BMP-7 in chondrocyte main-
tenance and cartilaginous extracellular matrix synthesis. Although
previously speciﬁc Smad-signalling has been linked to the chon-
drogenic fate40, it remains elusive whether the herein found dif-
ferential action of BMP-2 and BMP-7 can be explained by speciﬁc
Smad activation. In addition BMPs can also induce signalling
through MAP (mitogen activated protein) kinases and thereby in-
ﬂuence the chondrogenic outcome41. We are currently evaluating
the above options.
As a link between BMP-2 and chondrocyte hypertrophy has
been established previously23,42 we here speciﬁcally further
focussed on a possible mechanism which could explain the
hypertrophy-suppressing action of BMP-7. Focussing on Sox9 and
Runx2 as key factors in regulating the balance between chondro-
genic maintenance and chondrocyte hypertrophy, it was reported
previously that Sox9 is able to repress Runx2 expression via the
Runx2 transcriptional repressor Bapx1/Nkx3.225,27,28. Bapx1/
Nkx3.2 is a transcriptional target of Sox9 and thus the BMP-7-
induced Sox9 levels may prevent Runx2 induction via upregulat-
ing Bapx1/Nkx3.225. In addition to suppressing the transcription of
Runx2, Bapx1/Nkx3.2 was recently found to be directly involved in
driving the transcription of Col2a143, providing an potential alter-
native route via which the BMP-7-induced Bapx1/Nkx3.2 may
balance the hypertrophic fate of a chondrocyte. However, knock-
down of Bapx1/Nkx3.2 in ATDC5 showed only moderate/non-
signiﬁcant effects on Col2a1 mRNA levels, making it conceivable
that the hypertrophy-suppressive action of BMP-7 via Bapx1/
Nkx3.2 in ATDC5 is mainly via an active hypertrophy-suppressing
route rather than an active pro-chondrogenic (Col2a1) mecha-
nism. Another possible determinant in the Bapx1/Nkx3.2 depend-
ing BMP-7 action could be parathyroid hormone related peptide
(PTHrP). Our unpublished data show that PTHrP expression is
upregulated upon exposure to BMP-7. Previously it has been
reported that maintenance of Bapx1/Nkx3.2 expression in growth
plate proliferative chondrocytes depends on PTHrP signals28 and
that BMP and PTHrP signalling interact13. Finally, sonic hedgehog
(Shh) has been reported to induce Bapx1/Nkx3.2 expression to
induce somitic chondrogenesis in avian progenitor cells44. It was
found that Nkx3.2 (like Shh) can only induce somitic chondro-
genesis in the presence of a BMP signal. These ﬁndings may provide
alternative explanations through which BMP-7 might execute its
hypertrophy-suppressive action, although at this stage it is not
clear what the potential relative contribution of these alternative
pathways is to control expression of Bapx1/Nkx3.2. Furthermore, it
is well known that Sox9 is regulated by BMP activity in vitro andin vivo14,45,46. This was conﬁrmed in our study for BMP-2 and BMP-
7. In view of a Sox9-dependent expression of Bapx1/Nkx3.2 it was
therefore surprising that we did not measure induction of Bapx1/
Nkx3.2 in both BMP conditions. This discrepancy may be explained
by potential BMP-speciﬁc differential signalling pathways down-
stream of different BMP receptors, allowing (Sox9-driven) Bapx1/
Nkx3.2 expression in the BMP-7 conditions, while not supporting
this upon signalling by BMP-2. This, however, remains speculation.
In conclusion, we here show that BMP-2 and BMP-7 have dif-
ferential actions during chondrogenic differentiating of chon-
droprogenitor cells: BMP-2 acts a speciﬁc inducer of chondrocyte
hypertrophy, while BMP-7 appears to increase or maintain chon-
drogenic potential and prevent chondrocyte hypertrophy. These
results may provide a rationale for an application-dependent use of
speciﬁc BMPs in endochondral-based cartilage and bone regener-
ative techniques.
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